Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch P… Read more
Beta Bionics, Inc. Common Stock (BBNX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.030x
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has a cash flow conversion efficiency ratio of -0.030x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.73 Million) by net assets ($294.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beta Bionics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Beta Bionics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beta Bionics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
0.008x |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
N/A |
|
Shenzhen Everbest Machinery Indus
SHE:002980
|
0.002x |
|
Beijing Hanbang Technology Corp
SHE:300449
|
-0.118x |
|
Hana Tour
KO:039130
|
0.546x |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
0.012x |
|
Shandong Homey Aquatic Development Co Ltd
SHG:600467
|
0.015x |
|
BRIDGE INV.GRP.HLD.A -01
F:53S
|
N/A |
Annual Cash Flow Conversion Efficiency for Beta Bionics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Beta Bionics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.01 Million | $-48.27 Million | -0.635x | -14.72% |
| 2023-12-31 | $58.61 Million | $-32.45 Million | -0.554x | +88.05% |
| 2022-12-31 | $13.00 Million | $-60.21 Million | -4.631x | -- |